Stratowa C, Wilgenbus K K
Department of Exploratory Research, Boehringer Ingelheim, Austria Ges mbH, Dr Boehringergasse 5-11, Vienna, Austria.
Curr Opin Mol Ther. 1999 Dec;1(6):671-9.
Recent advances in technology, especially the merger between molecular biology, automation technology and computer science, are rapidly changing the manner in which pharmaceutical companies will discover new drug targets and develop new therapeutic drugs. One example of such a merger between different disciplines has been the development of technology platforms, such as cDNA microarrays and oligonucleotide arrays, allowing the generation of comprehensive gene expression profiles in a previously insurmountable throughput. Hereby, the major limitation is currently shifting from the efficient generation of biological information to the extraction of biological knowledge. However, given the foreseeable developments in data mining technologies and diverse computational biology tools, it can be anticipated that this information will foster the effectiveness to develop new and hopefully better drugs.
技术的最新进展，尤其是分子生物学、自动化技术与计算机科学之间的融合，正在迅速改变制药公司发现新药物靶点和开发新治疗药物的方式。不同学科之间这种融合的一个例子是技术平台的发展，如cDNA微阵列和寡核苷酸阵列，它们能够以前所未有的通量生成全面的基因表达谱。因此，目前的主要限制正从生物信息的高效生成转向生物知识的提取。然而，鉴于数据挖掘技术和各种计算生物学工具可预见的发展，可以预期这些信息将提高开发新的、有望更好的药物的效率。
